Rare T263P epidermal growth factor receptor extracellular domain mutation of advanced non-small cell lung cancer in a Vietnamese male patient

Kien Hung Do; Tai Van Nguyen; Tu Anh Do; Duc Thanh Le; Phuong Thi Bich Nguyen; Chu Van Nguyen

doi:10.1002/rcr2.1170

Rare T263P epidermal growth factor receptor extracellular domain mutation of advanced non-small cell lung cancer in a Vietnamese male patient

Respirol Case Rep. 2023 Jun 1;11(7):e01170. doi: 10.1002/rcr2.1170. eCollection 2023 Jul.

Authors

Kien Hung Do^{1

2}, Tai Van Nguyen^{1

2

3}, Tu Anh Do¹, Duc Thanh Le¹, Phuong Thi Bich Nguyen^{1

2

3}, Chu Van Nguyen¹

Affiliations

¹ Vietnam National Cancer Hospital-K Hospital Hanoi Vietnam.
² Department of Medical Oncology I Vietnam National Cancer Hospital-K Hospital Hanoi Vietnam.
³ PhD student in Oncology Hanoi Medical University Hanoi Vietnam.

Abstract

T263P mutation is one of the rare EGFR mutations located on chromosome 7p11.2, which is a change in amino acid residue at position 263 of the epidermal growth factor receptor protein, where L-threonine has been replaced by L-proline. This missense mutation in the extracellular EGFR domain is not well-known in lung cancer. In this study, we first report a patient with advanced lung adenocarcinoma harbouring only a rare T263P EGFR mutation who benefited from first-line afatinib therapy in Vietnam. The patient achieved a partial response with a time-to-treatment failure of 5 months. The patient subsequently received several chemotherapy regimens as the disease progressed, with overall survival of 17 months. Non-small cell lung cancer with a rare T263P EGFR mutation responds to afatinib but has a poor prognosis. Further studies are needed to determine the efficacy of targeted therapies in this specific population.

Keywords: NSCLC; T263P mutation; extracellular EGFR mutation.

Publication types

Case Reports